Monday, October 2, 2023
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Assistant Professor
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
This activity is intended for dermatologists, hematologists/oncologists, nurses, and emergency medicine physicians.
The goal of this activity is to educate members of the multidisciplinary and interprofessional cancer care team on recognizing and understanding how to manage immune-mediated adverse events (imAEs) related to the use of immune checkpoint inhibitors in the management of multiple cancers.
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Assistant Professor
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 1.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Awarded 1.25 contact hour(s) of continuing nursing education for RNs and APNs; 1.25 contact hours are in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 6/21/2019
Valid for credit through: 6/21/2020, 11:59 PM EST
processing....
The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.
 |
Mary is a 56-year-old woman who is being treated with pembrolizumab as a first-line therapy for non-small–cell lung cancer (NSCLC) that has metastasized to her liver. At the appointment for her fourth treatment, she mentions a rash on her arms. Several flat reddish pink patches of skin covered with small confluent bumps are observed on her forearms, with no involvement of her upper arms (Figure 1). She says the rash manifested several days earlier and indicates there was no associated burning, blistering or pain but that she had some mild itching earlier that morning, which subsided after she showered and applied her usual moisturizing lotion. A review of her medical history reveals no autoimmune diseases such as lupus nor immune-related skin condition such as psoriasis or lichen planus. Her only other medication is pravastatin for hyperlipidemia, which she has been taking for the past 4 years with no recent dosing modifications. No other parts of her body are affected and she reports no other symptoms.
Figure 1. Maculopapular Rash
